GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » ROE %

RxSight (RxSight) ROE % : -22.45% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RxSight ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. RxSight's annualized net income for the quarter that ended in Mar. 2024 was $-36.4 Mil. RxSight's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $162.1 Mil. Therefore, RxSight's annualized ROE % for the quarter that ended in Mar. 2024 was -22.45%.

The historical rank and industry rank for RxSight's ROE % or its related term are showing as below:

RXST' s ROE % Range Over the Past 10 Years
Min: -58.52   Med: 4980.58   Max: Negative Equity
Current: -28.23

During the past 5 years, RxSight's highest ROE % was Negative Equity%. The lowest was -58.52%. And the median was 4,980.58%.

RXST's ROE % is ranked worse than
69.61% of 803 companies
in the Medical Devices & Instruments industry
Industry Median: -0.27 vs RXST: -28.23

RxSight ROE % Historical Data

The historical data trend for RxSight's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight ROE % Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Negative Equity Negative Equity - -58.52 -38.85

RxSight Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.99 -36.54 -31.17 -22.81 -22.45

Competitive Comparison of RxSight's ROE %

For the Medical Devices subindustry, RxSight's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RxSight's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RxSight's ROE % distribution charts can be found below:

* The bar in red indicates where RxSight's ROE % falls into.



RxSight ROE % Calculation

RxSight's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-48.608/( (89.902+160.362)/ 2 )
=-48.608/125.132
=-38.85 %

RxSight's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-36.4/( (160.362+163.929)/ 2 )
=-36.4/162.1455
=-22.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


RxSight  (NAS:RXST) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-36.4/162.1455
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-36.4 / 118.048)*(118.048 / 182.8575)*(182.8575 / 162.1455)
=Net Margin %*Asset Turnover*Equity Multiplier
=-30.83 %*0.6456*1.1277
=ROA %*Equity Multiplier
=-19.9 %*1.1277
=-22.45 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-36.4/162.1455
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-36.4 / -36.364) * (-36.364 / -42.68) * (-42.68 / 118.048) * (118.048 / 182.8575) * (182.8575 / 162.1455)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.001 * 0.852 * -36.15 % * 0.6456 * 1.1277
=-22.45 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


RxSight ROE % Related Terms

Thank you for viewing the detailed overview of RxSight's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


RxSight (RxSight) Business Description

Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
Ilya Goldshleger officer: Chief Operating Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg officer: Chief Commercial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md director, officer: See Remarks C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen officer: Chief Financial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms director LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano director 110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

RxSight (RxSight) Headlines

From GuruFocus

RxSight, Inc. Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 05-16-2022

RxSight, Inc. Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-09-2023

RxSight, Inc. Announces Pricing of Public Offering of Common Stock

By Stock market mentor Stock market mentor 02-08-2023

RxSight, Inc. Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 02-07-2023

RxSight, Inc. Reports First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews 07-05-2022